Valeritas Holdings, Inc.

Equities

VLRXQ

US91914N3017

Medical Equipment, Supplies & Distribution

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-4.76%	-96.52%

2020	Valeritas Holdings, Inc. Went Out of Business	CI
2020	First Amended Combined Joint Liquidation Plan & Disclosure Statement Approved for Valeritas Holdings, Inc.	CI

Valeritas, Inc. Announces Management Changes

February 25, 2016 at 01:00 pm

Valeritas, Inc. announced changes to its executive team. John Timberlake has been named the company's new Interim Chief Executive Officer. Former CEO Kris Peterson is leaving Valeritas to pursue other opportunities and will continue to consult with the company.

Valeritas also announced changes in its Board of Directors. Luke Duster, Managing Director of CRG, will join the board along with Nate Hukill, President of CRG, Cameron Hui, Associate of CRG, and John Timberlake. John is a pharmaceutical industry veteran with 25 years of pharmaceutical and medical device experience, and 16 of those years in metabolism and diabetes.

He joined Valeritas in 2006 and served in executive positions including most recently as President and Chief Commercial Officer.

Latest news about Valeritas Holdings, Inc.

Valeritas Holdings, Inc. Went Out of Business	30/06/20	CI
First Amended Combined Joint Liquidation Plan & Disclosure Statement Approved for Valeritas Holdings, Inc.	08/06/20	CI
First Motion for Exclusivity Period Extension Approved For Valeritas Holdings, Inc.	03/06/20	CI
First Motion for Exclusivity Period Extension Filed by Valeritas Holdings, Inc.	21/05/20	CI
Combined Disclosure Statement and Liquidation Plan Approved for Solicitation Purpose on Interim Basis for Valeritas Holdings, Inc.	21/04/20	CI
First Amended Combined Joint Liquidation Plan & Disclosure Statement Filed by Valeritas Holdings, Inc.	15/04/20	CI
Combined Joint Liquidation Plan & Disclosure Statement Filed by Valeritas Holdings, Inc.	06/04/20	CI
Valeritas Holdings, Inc. Announces Management Changes	02/04/20	CI
Zealand Pharma A/S completed the acquisition of substantially all assets of Valeritas Holdings, Inc.	01/04/20	CI
Motion for Asset Sale Approved for Valeritas Holdings, Inc.	20/03/20	CI
Final DIP Financing Approved for Valeritas Holdings, Inc.	13/03/20	CI
Notice for Auction Cancellation Filed by Valeritas Holdings, Inc.	13/03/20	CI
Bidding Procedure Approved for Valeritas Holdings, Inc.	06/03/20	CI
Valeritas Holdings, Inc. Terminates Joseph Saldanha as Chief Business Officer, Effective from March 6, 2020	28/02/20	CI
Valeritas Holdings, Inc.(OTCPK:VLRX.Q) dropped from NASDAQ Composite Index	19/02/20	CI
The United States Bankruptcy Court for the District of Delaware Enters an Order Granting an Interim Approval to Valeritas Holdings, Inc.'s Proposed Senior Secured Priming Debtor-In-Possession Financing Facility	14/02/20	CI
Interim DIP Financing Approved for Valeritas Holdings, Inc.	14/02/20	CI
Asset Purchase Agreement Filed by Valeritas Holdings, Inc.	14/02/20	CI
Valeritas Holdings, Inc.(NasdaqCM:VLRX) dropped from S&P TMI Index	12/02/20	CI
Motion for Joint Administration Approved for Valeritas Holdings, Inc.	12/02/20	CI
Motion for Asset Sale Filed by Valeritas Holdings, Inc.	10/02/20	CI
Valeritas Holdings, Inc. Filed for Bankruptcy	09/02/20	CI
Motion for Joint Administration Filed by Valeritas Holdings, Inc.	09/02/20	CI
Zealand Pharma A/S entered into a stalking horse agreement to acquire substantially all assets of Valeritas Holdings, Inc.	08/02/20	CI
Valeritas Holdings, Inc. Announces Appointment of Melanie Hansen as Treasurer and Principal Accounting Officer, Effective January 13, 2020	10/01/20	CI

Chart Valeritas Holdings, Inc.

Duration

Period

More charts

Company Profile

Valeritas Holdings, Inc. is a United States-based medical technology company. The Company's product, V-Go Wearable Insulin Delivery device (V-Go), is a wearable, basal-bolus insulin delivery device for adult patients requiring insulin that enables patients to administer a continuous preset basal rate of insulin over 24 hours. V-Go is a small wearable and completely disposable insulin delivery device that a patient adheres to his or her skin every 24 hours. V-Go enables patients to closely mimic the body's normal physiologic pattern of insulin delivery throughout the day and to manage their diabetes with insulin without the need to plan a daily routine around multiple daily injections. It has developed V-Go utilizing its h-Patch platform as a patient-focused solution to address insulin therapies. Its h-Patch platform facilitates the subcutaneous delivery of injectable medicines to patients across a range of therapeutic areas.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
VALERITAS HOLDINGS, INC.	-96.52%	167K
ABBOTT LABORATORIES	-5.56%	181B
MEDTRONIC PLC	-0.11%	108B
BECTON, DICKINSON AND COMPANY	-6.17%	66.12B
DEXCOM, INC.	+2.64%	50.65B
CENCORA, INC.	+6.58%	43.66B
HOYA CORPORATION	+4.91%	41.3B
METTLER-TOLEDO INTERNATIONAL, INC.	+21.98%	31.6B
TERUMO CORPORATION	+14.45%	25.03B
WEST PHARMACEUTICAL SERVICES, INC.	-5.81%	24.16B

Other Medical Equipment, Supplies & Distribution